Vitamin B3 to boost immunotherapy for bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether taking vitamin B3 can help immunotherapy work better for people with bladder cancer. It’s for patients who have a certain type of bladder cancer and have had a recent infection that needed antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have bladder cancer that has not spread beyond the bladder (stages cT2 to cT4a N0 M0).
- You had an infection that required antibiotics within 30 days to 1 day before starting treatment.
- Your organs (like kidneys, liver, and blood cells) are working well enough for the study.
- You have not had prior treatment with an immunotherapy drug like a PD-1 or PD-L1 blocker.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
This trial tests if taking probiotics can help people with advanced bladder or urinary tract cancer that has spread. It's for those who have already tried immunotherapy. The goal is to see if probiotics can improve treatment outcomes.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
This trial tests a combination of probiotics, targeted therapy, and immunotherapy aimed at preserving the bladder in people with muscle-invasive bladder cancer. It's for those who can't have standard surgery or cisplatin chemo, and whose tumors have a certain protein (HER2).
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
This trial tests adding high-dose vitamin C (ascorbate) to a standard chemotherapy combination for people with muscle-invasive bladder cancer who cannot take or choose not to take cisplatin. The goal is to find a more affordable and effective treatment option.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.